ST Pharm Enters Gene Therapy and Vaccine CDMO Market

[Asia Economy Reporter Hyun-ui Cho] ST Pharm announced on the 2nd that it is entering the contract development and manufacturing organization (CDMO) business for gene therapy and vaccines based on messenger RNA (mRNA), which carries genetic information.

ST Pharm established an mRNA Business Development Office directly under the CEO and recruited Dr. Juseong Yang, an expert in the gene therapy field, as the head of the Business Development Office. Dr. Yang has served as the head of research institutes at Bioneer and Plumline Life Sciences, conducting research on core technologies for immunotherapy, and holds foundational patents related to DNA vaccines.

Through this new business entry, ST Pharm will engage in the development of mRNA-based therapeutics and vaccines. mRNA-based therapeutics and vaccines work by directly delivering mRNA into patient cells to produce specific proteins, thereby treating diseases caused by protein deficiencies or inducing the direct production of antibodies against infectious agents.

An ST Pharm official stated, "We plan to first expand our business as a CDMO for mRNA-based therapeutics," adding, "In the future, we also plan to develop our own new drugs in the fields of antiviral, anticancer, and immunotherapy using mRNA."

This content was produced with the assistance of AI translation services.